DEXTROMETHORPHAN HBR AND GUAIFENESIN

N/A

Manufactured by Cardinal Health 110, LLC. DBA Leader

224 FDA adverse event reports analyzed

Last updated: 2026-04-15

About DEXTROMETHORPHAN HBR AND GUAIFENESIN

DEXTROMETHORPHAN HBR AND GUAIFENESIN is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Cardinal Health 110, LLC. DBA Leader. The most commonly reported adverse reactions for DEXTROMETHORPHAN HBR AND GUAIFENESIN include COVID-19, DISEASE RECURRENCE, DYSPNOEA, ASTHENIA, CARDIAC ARREST. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for DEXTROMETHORPHAN HBR AND GUAIFENESIN.

Top Adverse Reactions

COVID 1910 reports
DISEASE RECURRENCE7 reports
DYSPNOEA7 reports
ASTHENIA6 reports
CARDIAC ARREST5 reports
COUGH5 reports
FALL5 reports
PAIN5 reports
PAIN IN EXTREMITY5 reports
PNEUMONIA5 reports
RESPIRATORY ARREST5 reports
DIARRHOEA4 reports
DRUG INEFFECTIVE4 reports
FATIGUE4 reports
FEELING ABNORMAL4 reports
HEADACHE4 reports
NASOPHARYNGITIS4 reports
WEIGHT DECREASED4 reports
BLOOD PRESSURE INCREASED3 reports
CONDITION AGGRAVATED3 reports
CONFUSIONAL STATE3 reports
DEATH3 reports
DIZZINESS3 reports
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION3 reports
MALAISE3 reports
NAUSEA3 reports
PARAESTHESIA3 reports
PRODUCT USE IN UNAPPROVED INDICATION3 reports
URINARY TRACT INFECTION3 reports
ABNORMAL BEHAVIOUR2 reports
ARTHRALGIA2 reports
ATRIAL FIBRILLATION2 reports
BALANCE DISORDER2 reports
BRONCHITIS2 reports
DEPRESSION2 reports
EPISTAXIS2 reports
FEELING HOT2 reports
FLUSHING2 reports
HALLUCINATION, VISUAL2 reports
HERNIA2 reports
HOSPITALISATION2 reports
INFLUENZA LIKE ILLNESS2 reports
INTENTIONAL DRUG MISUSE2 reports
MEMORY IMPAIRMENT2 reports
MULTIPLE ALLERGIES2 reports
OFF LABEL USE2 reports
PRODUCT DOSE OMISSION ISSUE2 reports
PRURITUS2 reports
PYREXIA2 reports
SEASONAL ALLERGY2 reports
SOMNOLENCE2 reports
THERAPEUTIC RESPONSE UNEXPECTED2 reports
UNEVALUABLE EVENT2 reports
URTICARIA2 reports
VERTIGO2 reports
VIRAL INFECTION2 reports
ABDOMINAL HERNIA1 reports
ABNORMAL DREAMS1 reports
ACCIDENTAL OVERDOSE1 reports
ADMINISTRATION SITE PAIN1 reports
ADMINISTRATION SITE SWELLING1 reports
AGEUSIA1 reports
ALLERGY TO ARTHROPOD STING1 reports
ARRHYTHMIA SUPRAVENTRICULAR1 reports
ARTHRITIS1 reports
ARTHROPOD BITE1 reports
BACK PAIN1 reports
BLOOD GLUCOSE INCREASED1 reports
BLOOD POTASSIUM DECREASED1 reports
BLOOD PRESSURE ABNORMAL1 reports
BLOOD SODIUM DECREASED1 reports
BRONCHIECTASIS1 reports
BURNING SENSATION1 reports
CATHETER SITE ERYTHEMA1 reports
CATHETER SITE PAIN1 reports
CATHETER SITE RELATED REACTION1 reports
CATHETER SITE SWELLING1 reports
CHEST PAIN1 reports
CHILLS1 reports
CHOLECYSTECTOMY1 reports
CHRONIC SINUSITIS1 reports
CLUSTER HEADACHE1 reports
COLD URTICARIA1 reports
COMPLETED SUICIDE1 reports
CONJUNCTIVITIS1 reports
CONSTIPATION1 reports
CONTUSION1 reports
CYSTITIS1 reports
DEHYDRATION1 reports
DELIRIUM1 reports
DELUSION1 reports
DEMENTIA1 reports
DEVICE DELIVERY SYSTEM ISSUE1 reports
DEVICE INFORMATION OUTPUT ISSUE1 reports
DEVICE RELATED THROMBOSIS1 reports
DEVICE USE CONFUSION1 reports
DISCOMFORT1 reports
DISORIENTATION1 reports
DISTURBANCE IN ATTENTION1 reports
DRUG ABUSE1 reports

Report Outcomes

Out of 72 classified reports for DEXTROMETHORPHAN HBR AND GUAIFENESIN:

Serious 47.2%Non-Serious 52.8%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Female36 (54.5%)
Male30 (45.5%)

Reports by Age

Age 644 reports
Age 623 reports
Age 653 reports
Age 663 reports
Age 693 reports
Age 272 reports
Age 522 reports
Age 532 reports
Age 582 reports
Age 592 reports
Age 712 reports
Age 802 reports
Age 842 reports
Age 171 reports
Age 291 reports
Age 321 reports
Age 331 reports
Age 351 reports
Age 391 reports
Age 411 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with DEXTROMETHORPHAN HBR AND GUAIFENESIN?

This profile reflects 224 FDA FAERS reports that mention DEXTROMETHORPHAN HBR AND GUAIFENESIN. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for DEXTROMETHORPHAN HBR AND GUAIFENESIN?

Frequently reported terms in FAERS include COVID-19, DISEASE RECURRENCE, DYSPNOEA, ASTHENIA, CARDIAC ARREST, COUGH. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures DEXTROMETHORPHAN HBR AND GUAIFENESIN?

Labeling and FAERS entries often list Cardinal Health 110, LLC. DBA Leader in connection with DEXTROMETHORPHAN HBR AND GUAIFENESIN. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.